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Background: Malaria in pregnancy is one of the most common preventable causes of maternal and neonatal
morbidity and mortality in sub-Saharan Africa. To prevent its adverse effects, such as maternal anaemia, placental
parasitaemia and low birth weight (LBW) neonates, the World Health Organization recommends effective malaria case
management, use of insecticide-treated bed nets and intermittent preventive therapy in pregnancy (IPTp).
Sulphadoxine-pyrimethamine (SP) has been the standard for IPTp in several countries, but parasite resistance to SP is
growing. Therefore, new IPTp therapies are urgently needed. One candidate being evaluated for IPTp is a fixed-dose
combination of azithromycin and chloroquine (AZCQ). This paper describes the challenges and the innovative solutions
implemented in designing and conducting a pivotal AZCQ-IPTp trial, sponsored by Pfizer Inc and co-funded by Pfizer
Inc and the Medicines for Malaria Venture.
Methods: The AZCQ-IPTp pivotal trial is a multicentre, multicountry, phase III, open-label, randomized superiority study
of AZCQ-IPTp versus SP-IPTp in pregnant women of sub-Saharan Africa. The trial was designed to meet stringent
regulatory agency scientific advice and IPTp policy makers’ recommendations, and incorporates an innovative adaptive
design to manage programme risk, maintain the operating characteristics of the study and optimize resources. The
trial’s novel composite primary endpoint is the proportion of participants with a suboptimal pregnancy outcome
(abortion [≤28 weeks], stillbirths [>28 weeks], premature [<37 weeks] deliveries, LBW [<2,500 g] live neonates, missing
neonatal birth weight data or loss to follow-up). The study employs a prospective group sequential design with three
unblinded analyses when 50%, 70% and 100% of participants achieve the primary endpoint; the study team will remain
blinded to the analyses until after the completion of the study. The number of participants randomized will be
adaptive, based on the blinded review of the observed pooled primary endpoint data across the two treatment arms,
when approximately 1,000 participants complete the primary endpoint assessments.
Results: This study is ongoing and expected to complete in 2014.
Conclusion: This report describes the unique challenges and innovative solutions implemented in designing and
conducting this pivotal AZCQ-IPTp trial, which may serve as a prototype for future IPTp and other studies involving
similar conditions.
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Malaria in pregnancy (MiP) is one of the most common
preventable causes of maternal and neonatal mortality
and morbidity in sub-Saharan Africa. In 2007, 54.5 million
pregnancies were at risk in stable and high Plasmodium
falciparum transmission areas of sub-Saharan Africa, and
another 70.5 million in areas with Plasmodium vivax only
or low transmission [1].
The common adverse outcomes of malaria infection in
pregnant women, with considerable acquired immunity,
living in areas of high and stable P. falciparum malaria
transmission, include maternal anaemia, placental para-
sitaemia and low birth weight (LBW; weighing <2,500 g)
neonates [2-5]. LBW is primarily a result of placental
infection and consequent intra-uterine growth retarda-
tion [3]. Primigravidae and secundigravidae women have
higher prevalence of maternal malaria infection (periph-
eral and placental parasitaemia) and their neonates are
at higher risk of LBW [4]. LBW has been associated with
an increased risk of morbidity and mortality [6-8]. Inter-
mittent preventive therapy in pregnancy (IPTp) is one of
the key strategies recommended by the World Health
Organization (WHO) Global Malaria Programme (GMP)
for malaria control in areas of stable and high malaria
transmission where many pregnant women with mal-
aria infection remain asymptomatic [9]. The WHO’s
recommended strategies include both curative (effective
case management of malaria and anaemia) and preventive
(insecticide-treated nets and intermittent preventive ther-
apy) measures [10]. IPTp is expected to improve pregnancy
outcomes by clearing asymptomatic parasitaemia, treating
and/or preventing placental malaria and by preventing
malaria and its adverse consequences. IPTp is based on
the administration of a complete curative dosing regi-
men of (an) anti-malarial drug(s) at routine periodic ante-
natal visits during pregnancy and may provide protection
over and above any protection provided by the use of
bed nets [10].
Recent studies have shown that a wide range (27% to
58%) of women attending an antenatal care facility in
sub-Saharan Africa were positive for P. falciparum parasit-
aemia [11-15]. One study estimated that universal cover-
age with IPTp would reduce all-cause neonatal mortality
by 32% [16]. Based on the evidence of significant reduc-
tion in LBW neonates, placental malaria and maternal an-
aemia following the use of sulphadoxine-pyrimethamine
(SP) in pregnant women, the WHO recommended SP as
the standard of care for IPTp [17]. The 2012 WHO IPTp
guidelines recommend that all pregnant women in areas
of moderate and high malaria transmission receive SP-
IPTp at each antenatal visit in the second and third
trimester [17].
Several countries in sub-Saharan Africa had adopted
SP-IPTp in their national malaria control programmesand antenatal care guidelines at the end of 2010 [18,19].
However, growing resistance to SP in recent years has be-
come a cause for concern, especially in East and Southern
Africa [20-22]. Hence, there is an urgent need for devel-
oping an effective replacement for SP-IPTp.
An ideal drug for IPTp needs to be safe and well toler-
ated in pregnancy, and efficacious in preventing the det-
rimental effects of malaria on the mother and the foetus.
To limit the development of resistance, an IPTp drug
should not be used as first-line treatment for symptom-
atic malaria [23]. Very few drug candidates or their com-
binations meet these criteria.
The Malaria in Pregnancy Consortium is currently
investigating mefloquine (ClinicalTrials.gov identifier
NCT00811421) and a dihydroartemisinin-piperaquine
combination (NCT01669941 and NCT01231113) for IPTp.
However, the use of the dihydroartemisinin-piperaquine
combination could be limited by the known tolerability
and neuropsychiatric issues associated with its use, espe-
cially in women [24]. The recent efforts of the Medicines
for Malaria Venture (MMV) to develop a better tolerated
enantiomer of mefloquine failed to demonstrate any ad-
vantage over the commercially available mefloquine [25].
A fixed-dose combination of azithromycin (AZ) and
chloroquine (CQ), AZCQ, is currently under investiga-
tion for IPTp. The combination of AZ and CQ has
demonstrated additive to synergistic activity against P.
falciparum in vitro [26,27]. In a phase II clinical study
in symptomatic uncomplicated P. falciparum malaria,
AZ and CQ monotherapies were suboptimal in efficacy
(33% and 27%, respectively); however, when AZ and CQ
were co-administered, the efficacy was 97% [28]. Co-
administration of AZ and CQ has demonstrated efficacy,
safety and tolerability in two multi-country phase II/III
clinical studies in the treatment of symptomatic uncom-
plicated P. falciparum malaria in adults in sub-Saharan
Africa [28,29]. AZ and CQ have been on the market for
several years and have extensive safety experience in
adults, children and pregnant women. Both AZ and CQ
have been widely used in all trimesters of pregnancy and
are considered safe in pregnant women as individual
agents [30]. The activity of AZ against common sexually
transmitted infections (STIs) including gonorrhoea and
chlamydial infections [30,31] could be an added benefit in
improving pregnancy outcomes.
IPTp is recommended for high and stable malaria trans-
mission regions, primarily in sub-Saharan Africa. To en-
sure review by a well-established regulatory agency, before
seeking African regulatory approvals, the regulatory dos-
sier for the AZCQ-IPTp programme will be submitted to
the European Medicines Agency (EMA) under Article 58
for a Committee for Medicinal Products for Human Use
(CHMP) Scientific Opinion. Article 58 is a new mechan-
ism for products developed for countries outside the
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health interest by the WHO [32]. The EMA evaluates such
dossiers in cooperation with the WHO for safety, efficacy,
quality and risk-benefit for the populations for which the
product is intended [32]. The EMA review and opinion
will be important for subsequent review and approvals
from African regulatory agencies and for the inclusion of
AZCQ in WHO and African national policy guidelines to
ensure access and delivery to pregnant women in areas of
high malaria transmission.
This article describes the challenges in designing and
conducting a phase III IPTp clinical trial and the innova-
tive approaches being used to overcome these challenges.
Methods
Methodological issues in designing IPTp clinical trials
Absence of regulatory guidance
While SP-IPTp is included in policy guidelines for several
countries in Africa, it has never been evaluated by any
well-established regulatory bodies that review new drug
applications, such as the EMA or US Food and Drug Ad-
ministration. No regulatory guidance document is avail-
able on how to evaluate an investigational treatment for
IPTp. Hence, from a regulatory perspective, IPTp is an
unprecedented indication. To be accessible to the target
population, a new IPTp drug would require approval by
the national regulatory agencies and inclusion in the pol-
icy guidelines of the WHO and the National Malaria Con-
trol and Reproductive Health Programs. The standard
IPTp trial designs used for the evaluation of SP-IPTp are
not consistent with general clinical trial guidance from
well-established regulatory authorities.
Primary endpoint definition
When designing the study, a review of the literature be-
tween 1990 through 2008 indicated the use of different
endpoints as part of the primary endpoint, the three key
endpoints being LBW, maternal anaemia and placental
malaria. Moreover, there was no consistency in how these
endpoints were defined. The WHO/GMP recommends
LBW as an endpoint since it appears to correlate with
child survival [10]. Most recent IPTp studies to date have
used LBW as the primary endpoint; other trials have used
severe anaemia or placental parasitaemia as the primary
endpoint. While LBW seems to be widely accepted as the
primary endpoint among the malaria research commu-
nity, it has some limitations from a regulatory perspective
as described in the paragraph below.
The LBW endpoint recommended by the WHO and
used in several recently published IPTp studies is de-
fined as the proportion of study participants with LBW
(<2,500 g) live singleton neonates. The analysis of a LBW
endpoint in these studies excludes participants with other
suboptimal pregnancy outcomes, such as miscarriages,stillbirths and premature deliveries, and also excludes
participants with missing neonatal birth weight data or
participants who were lost to follow-up. Although not al-
ways clearly specified in IPTp clinical trials, the percent-
age of participants with incomplete information, such as
missing birth weight data or those lost to follow-up, varies
widely, with ranges between approximately 5% to 66% in
trials that reported this information [33-35]. Regulatory
agencies take a conservative approach and suggest inclu-
sion of all those participants listed above in the primary
endpoint analysis and categorize them as “failures” per
data analyses guidelines from the EMA [36]. As a conse-
quence, participants with any suboptimal pregnancy out-
come or missing data, including the unknown outcome of
pregnancy, absence of known birth weight and lost to
follow-up are considered “failures.”
Sample size determination
Typically, sample size is calculated taking into consider-
ation the estimated true effect size and the true incidence
of the primary endpoint in the control group population.
Since none of the IPTp studies to date have used the
composite endpoint of suboptimal pregnancy outcomes,
it is difficult to get a reliable estimate of the true incidence
of this endpoint in participants on the active control SP
arm. Moreover, even the incidence of the commonly used
primary endpoint of LBW with SP-IPTp from the ran-
domized controlled clinical trials reported in the literature
over the last 10 years varies widely, from 8% to 24%, de-
pending upon factors such as the gravidity (e.g. primigrav-
ida vs. multigravidae) and human immunodeficiency virus
status of participants included in the study, definition of
LBW endpoint (within 24 hours or within a week of deliv-
ery), concurrent use of insecticide-treated bed nets and
other interventions, SP resistance status of parasites, re-
gion where the study was conducted, timing of the study,
sample size and power of the study [37-39].
Effect size
A meta-analysis that included nine clinical trials conducted
between 1996 and 2006 demonstrated that SP-IPTp re-
duced placental malaria, LBW and maternal anaemia [20].
Five of these trials compared SP-IPTp with placebo or
case management and one study included the use of
insecticide-treated nets. In this study, AZCQ-IPTp is be-
ing compared with SP-IPTp in pregnant women. Per the
current standard of care, both treatment arms in the
study are using insecticide-treated bed nets; consequently,
the preventive effect of bed nets may further narrow the
gap between the two treatment arms and result in a lower
than expected effect size. Moreover, the effect size of SP-
IPTp for the composite endpoint of suboptimal preg-
nancy outcome is unknown since none of the IPTp
studies to date have evaluated this endpoint. More
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STIs could be additive towards improving pregnancy out-
comes and may positively impact the treatment effect in
comparison with SP-IPTp, but the magnitude of this effect
is unknown.
Rescue medication for symptomatic malaria
While an IPTp regimen should prevent and lower the
number of malaria episodes during the course of preg-
nancy, it is not aimed at completely eliminating them.
Hence, the study participants who develop symptom-
atic malaria during the study period are treated with
appropriate rescue anti-malarial medication, such as an
artemisinin-based combination or quinine as per local
standard of care guidelines. The anti-malarial effect of
any such rescue treatment could potentially confound
the IPTp effect of the study treatments.
Operational issues in conducting phase III IPTp trials in
sub-Saharan Africa
There are several practical challenges in conducting an
IPTp trial in sub-Saharan Africa. The suboptimal regional
regulatory infrastructure to evaluate a novel treatment, in-
adequate clinical research infrastructure, inexperience in
conducting clinical trials as per the International Confer-
ence on Harmonisation-Good Clinical Practice (ICH-GCP)
guidelines and stringent regulatory standards of western
agencies are some of the key issues that must be overcome
before initiating any study. In designing the AZCQ-IPTp
trial, these challenges had to be evaluated and measures
put in place to address them.
Results
AZCQ-IPTp pivotal trial design and conduct
This trial is sponsored and conducted by Pfizer Inc, is
co-funded by Pfizer Inc and the MMV and has an over-
sight by an independent external data monitoring com-
mittee (EDMC) with three-quarters membership from
sub-Saharan Africa. The clinical, statistical and regula-
tory plans and pivotal study design were discussed at
a scientific advice meeting with the Medicines and
Healthcare products Regulatory Agency (MHRA) in the
UK and its input was incorporated.
Trial design
The AZCQ-IPTp pivotal trial is an on-going multi-
centre, multi-country, phase III, open-label, randomized,
comparative, superiority study of AZCQ-IPTp versus
SP-IPTp in pregnant women in sub-Saharan Africa. The
trial, initiated in 2010, has been designed to meet both
regulatory and WHO/GMP IPTp guidelines and has an
adaptive design to manage programme risk as well as to
maintain the operating characteristics of the study, and
to optimize timelines and resource utilization.Primary endpoint
The pivotal study incorporates the composite endpoint of
a suboptimal pregnancy outcome as per MHRA Scientific
Advice that takes into account all missing data including
absence of birth weight information (e.g. in case of home
deliveries) and any loss to follow-up. The composite end-
point for this study was defined as the proportion of par-
ticipants with suboptimal pregnancy outcomes including
abortion (≤28 weeks), stillbirths (>28 weeks), premature
(<37 weeks) deliveries, LBW (<2,500 g) live neonates,
missing neonatal birth weight data or loss to follow-up.
Key secondary endpoints
The WHO/GMP recommended endpoint of occurrence
at birth of LBW (<2,500 g) live neonates is a key second-
ary endpoint in this study. The evaluation of this end-
point may be included in any decisions regarding the
potential incorporation of AZCQ in policy guidelines.
Other key secondary endpoints include commonly used
IPTp endpoints such as the occurrence of anaemia
(haemoglobin <11 g/dL) or severe anaemia (haemoglo-
bin <8 g/dL) at 36 to 38 weeks of gestation, occurrence
of placental parasitaemia at delivery, occurrence of pla-
cental malaria as determined by histology and number
of episodes of STIs per participant following the first
dose. The STIs were diagnosed based on the partici-
pant’s clinical presentation at any time between the first
dose of IPTp and delivery and/or laboratory test results
for the specimens collected between weeks 36–38
of gestation.
Sample size
The underlying true incidence of the primary endpoint
in the control group of this study is unknown, but has a
substantial impact on the required sample size. Based on
the wide range of suboptimal pregnancy outcome rates,
including LBW rates reported in recent IPTp studies,
the total number of participants to be enrolled ranges
from 2,602 to 5,044. To manage this uncertainty, the
study plans to enrol up to 5,044 participants; the sample
size will be finalized following the blinded review of the
observed proportion of the primary endpoint of sub-
optimal pregnancy outcomes in the pooled data across
the two groups after the first 1,000 participants have
achieved the primary outcome (Table 1). For example, if
the observed proportion of participants experiencing a
suboptimal pregnancy outcome is found to be 0.30, then
the total sample size will be 4,206. It should be noted
that the total sample size required will be calculated by
employing a group sequential design with the upper
bound of each interval assumed to be the true under-
lying proportion for the SP group. Owing to the lack
of reliable estimates in the literature for the primary
endpoint rate in the control group, and given that the
Table 1 Sample size determination
Observed pooled proportion for the primary




>0.28 to ≤0.32 4,206
>0.32 to ≤0.36 3,552
>0.36 to ≤0.40 3,030
>0.40 2,602
The design assumed a 20% risk reduction in the primary endpoint (relative
risk = 0.80, fixed-dose combination of azithromycin and chloroquine/
sulphadoxine-pyrimethamine [AZCQ/SP]). A 23% risk reduction (relative risk = 0.77,
AZCQ/SP) was assumed for low birth weight (key secondary endpoint).
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which in turn affects statistical power, the total number
of participants randomized is planned to be adaptive.
The sample size estimation assumed a 20% risk reduction
in the primary endpoint (relative risk = 0.80, AZCQ/SP). A
23% risk reduction (relative risk = 0.77, AZCQ/SP) was as-
sumed for LBW (key secondary endpoint). The 20% target
for the primary endpoint was considered a minimum clinic-
ally relevant treatment effect, and the 23% target for LBW
is a consequence of the fact that LBW is a component of
the primary endpoint.
Interim and final analyses
The AZCQ-IPTp study employs a group sequential de-
sign with three unblinded comparative analyses conducted
when 50%, 70% and 100% of participants complete the
primary endpoint visit. Group sequential stopping rules
will be used to stop the trial early for efficacy and futility
(non-binding) at each of the two sequential analyses.
The overall alpha level will be one-sided 0.000625,
controlled throughout the duration of the study using a
pre-specified alpha spending function, with an approxi-
mate overall power of 90% for establishing the superiority
of AZCQ over SP in a proportion of participants with
suboptimal pregnancy outcomes (primary endpoint). The
low alpha level of one-sided 0.000625 (equivalent to two-
sided 0.00125) is a regulatory requirement when a single
pivotal trial is used to demonstrate the same level of
evidence as two independent pivotal trials, without
actually performing a second trial. Secondary efficacy
endpoints will use an overall alpha level of two-sided 0.05.
Overall power, and equivalently the false negative
rate, will be maintained by employing a pre-specified
spending function.
Early stopping for positive efficacy will only occur if
both the proportion of participants with suboptimal preg-
nancy outcomes (primary endpoint) and the proportion of
participants with LBW (the first key secondary endpoint)
are statistically significantly lower in the AZCQ group
compared with the SP group, as evaluated by the relativerisk (primary analysis). The exact significance level used
will be derived from the alpha spending function at the
time of each interim analysis. If the total sample size is
5,044, therefore, the sample size for the interim analysis is
2,522, and based on the spending function used, the sig-
nificance level will be 0.0001 for the primary endpoint.
Similarly, the exact significance level used for judging fu-
tility will be derived from the beta spending function at
the time of each interim analysis. The sequential analyses
will use unblinded treatment codes and be prepared by a
group within Pfizer but external to the study team. The
study team will remain blinded to the results. The EDMC
will review the data every four months and recommend
stopping or continuing the study based on the interim re-
sults, predefined alpha and beta spending functions and
corresponding stopping boundaries and interim monitor-
ing output. The membership of the EDMC and its charter,
as well as the procedures for performing the interim ana-
lyses, were finalized and documented before the first in-
terim analysis.
Owing to the adaptive nature of the sample size deter-
mination, operating characteristics of the study design in
terms of power and Type I error rate were evaluated
using simulation. Probabilities for early stopping for
positive efficacy and futility at each of the interim ana-
lyses were evaluated as well. Type I error rates were sim-
ulated under the null hypothesis of no difference
(relative risk = 1.00). Each scenario under the alternative
hypothesis was run with 100,000 simulation iterations
to estimate the power. One million iterations were used,
under the null hypothesis, to determine the Type
I error rate for each stated true proportion for the
primary endpoint.
Trial conduct
As the overall goal of the IPTp programme is to identify a
potential replacement for SP, the study sites are located in
areas with stable and high malaria transmission where
SP-IPTp is included in national policy guidelines and SP
resistance has emerged as an issue of concern. The partici-
pating countries include Benin, Kenya, Malawi, Tanzania
and Uganda. Patient enrolment started in October 2010
and the study is estimated to complete in 2014.
Site selection and capacity building
The trial sites were selected based on the level of malaria
transmission, local SP resistance rates and rigorous pre-
trial site assessments by the monitoring and audit teams.
In addition, central laboratories in the region were audited
before their selection to identify gaps and plan training for
any deficiencies noted.
A number of processes have been put in place to ensure
conduct of the trial according to ICH-GCP standards and
smooth running of the day-to-day trial functions. The sites
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the trial conduct. A week-long investigator meeting was
conducted in Johannesburg to train site study teams
on ICH-GCP standards and Pfizer Standard Operating
Procedures (SOPs) related to study conduct, protocol
and laboratory assessments. Three-day hands-on ethics
workshops on research in vulnerable populations were
conducted in collaboration with the Steve Biko Centre of
Bioethics (Johannesburg, South Africa) for investigators
and ethics committee members for study sites. During
the four weeks preceding the enrolment of the first par-
ticipant, a five-day site initiation visit was conducted for
each site to train site teams on the practical aspects of
conducting the protocol as per ICH-GCP standards and
Pfizer SOPs. The site teams are now adequately resourced
to ensure compliance with the study protocol and ad-
equate documentation is required for regulatory sub-
missions. Each site team has engaged field workers
for home visits to ensure compliance with dosing, imple-
mentation of insecticide-treated bed nets and adverse
event monitoring.
The study has a robust monitoring plan. The first site
visit is conducted within two weeks of the enrolment of
the first patient and subsequent visits are conducted
every three to six weeks, depending upon the enrolment
rates and issues identified at previous visit(s). Each visit
lasts about a week. Medical monitoring is conducted by
Pfizer physicians on an on-going basis through a weekly
review of enrolment and adverse event logs from each
site, weekly teleconferences with the principal investiga-
tors for each site to review any clinical or safety issues
and a monthly review of protocol deviations and blinded
safety data from the Pfizer database populated from
monitored (i.e. quality-controlled) case report forms. Site
study teams are required to send information on emer-
ging serious adverse events to Pfizer’s Safety Group
within 24 hours of their first being aware of them. Emer-
ging safety data also are reviewed monthly by a cross-
functional clinical safety core group at Pfizer. In addition,
cross-functional risk management and product benefit
risk committees review the emerging data from all Pfizer-
sponsored AZ studies and published literature to iden-
tify and evaluate any new safety signals or trends and
update the benefit-risk assessment on an on-going basis.
Initial weekly enrolment rates are deliberately kept low to
give sites adequate time to get hands-on experience and
achieve operational excellence. Each site is audited by an
independent external audit agency early in the trial when
approximately 10% of study participants are enrolled. In
addition, internal quality review site visits are conducted
every three months by Pfizer’s clinical operations lead. A
root cause analysis is performed for any significant proto-
col deviations or issues identified during the monitoring,
quality review or audit visits, site teams are retrained andcorrective and preventive measures are put in place be-
fore sites can resume enrolment at optimum speed.
In addition, the EDMC, whose members include both
international and African experts in both malaria and
pregnancy, has been conducting a quarterly review of
emerging unblinded safety data and also will review the
interim analyses data. While the study is open-label, the
study team remains blinded to the emerging aggregate
safety data reviewed by the EDMC.
In the spirit of collaboration and to facilitate trial
application review, face-to-face meetings with African
national regulatory agencies were held prior to the sub-
mission of the clinical trial application. These meetings
provided an overview of the programme and clinical
study designs, and were especially important in view of
the unprecedented nature of the IPTp indication as
well as Pfizer’s intention to seek CHMP Article 58 scien-
tific opinion.Discussion
Despite widespread use, IPTp is an unprecedented indi-
cation from the regulatory perspective and there is cur-
rently no regulatory guidance on how to conduct an
IPTp trial for registration purposes. The published litera-
ture is not very informative in terms of designing a study
with the rigour required for stringent regulatory review.
To be accessible to pregnant women in sub-Saharan
countries who would need it the most, a new IPTp regi-
men needs to be incorporated into the malaria control
guidelines from the WHO/GMP, and following regula-
tory approval, in National Malaria Control and Repro-
ductive Health Programs. Therefore, when Pfizer and
the MMV initiated this AZCQ-IPTp trial, the team
sought input from diverse stakeholders. There were sev-
eral challenges in designing this trial, from selecting an
appropriate study design, endpoints and sample size to
the need for capacity building, including infrastructure
and trained personnel for appropriate patient monitoring
during the conduct of the study.
The innovative study design of the AZCQ-IPTp trial ad-
dresses the key challenges in designing and implementing
this type of study. In addition to maintaining proper oper-
ating characteristics, the adaptive nature of the trial design
will minimize any undue exposure of the pregnant women
to study drugs by optimizing sample size estimation and
through interim checks of the data. Given the unprece-
dented nature of the IPTp indication, early on during the
planning phase, a scientific advice meeting was held with
the MHRA.
Since the novel primary endpoint of suboptimal preg-
nancy outcomes may pose a challenge for policy makers
while comparing data from other ongoing studies of in-
vestigational IPTp products and regimens, the AZCQ-
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used IPTp endpoints as key secondary endpoints.
This study is being conducted according to ICH-GCP
standards that required the implementation of a number
of capacity-building initiatives such as infrastructure up-
grades, training in ICH-GCP guidelines, ethics work-
shops and a robust monitoring plan to ensure all study
personnel and procedures are in compliance with ICH-
GCP guidelines, auditing of regional laboratories, quali-
ty assurance and operational team visits to rectify
any deficiencies.
There are several limitations of this study. First, the pri-
mary endpoint of suboptimal pregnancy outcomes may
be less sensitive than the endpoint of LBW recommended
by the WHO and considered a standard primary end-
point. The composite endpoint of suboptimal pregnancy
outcomes may have categories of endpoints that may not
be affected by malaria or STI protective effect and hence
may dilute the overall IPTp effect. As a result, the study
may not be able to demonstrate superiority on the pri-
mary endpoint even though it may be positive on the end-
point of LBW, which is currently considered the more
relevant endpoint from the policy perspective. In addition,
the first 1,000 participants enrolled in the study predom-
inantly include those from the first two to three sites or
countries that started enrolling early, thereby having the
potential to provide less accurate sample size estimation.
This paper describes the challenges and innovative
solutions implemented in designing and conducting this
pivotal AZCQ-IPTp trial. Conducting a study as per
ICH-GCP standards for an unprecedented indication in
the resource-constrained setting of sub-Saharan Africa re-
quires significant capacity building, rigorous training and
intense monitoring, all of which can be very resource con-
suming. The high cost, coupled with the corporate liability
risk of conducting research in a vulnerable population in
these settings, may be one reason why the pharmaceutical
industry shies away from such much-needed trials. This
trial is being conducted by Pfizer in collaboration with the
MMV, a not-for-profit public private partnership founda-
tion with a mission to reduce the burden of malaria in
disease-endemic countries by discovering, developing and
facilitating delivery of new, effective and affordable anti-
malarial drugs. The MMV is not only providing financial
support for the clinical trial but also provides invaluable
scientific inputs and stakeholders engagement through a
team of malaria experts and its external expert scientif-
ic advisory committee. Public-private partnerships, such
as the Pfizer-MMV partnership, are one way that the
pharmaceutical industry may contribute to the successful
development of new medicines for vulnerable populations
in low-income countries. The design and conduct of this
study may serve as a prototype for future IPTp and other
studies where similar conditions exist.Abbreviations
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